Corcept Therapeutics is trading 26.5% up at $117.60 after a strong second-quarter earnings report that beat expectations and showcased a successful launch of its oncology drug Lifyorli.
- The company sharply raised its full-year 2026 revenue guidance, signaling accelerated growth and confidence in its transition into oncology.
- The substantial rerating reflects positive investor sentiment regarding the company's strategic shift and improving financial outlook.